Evolving Landscape of Pediatric Neurology: Erika Fullwood Augustine, MD, MS
May 5th 2023The associate chief science officer at Kennedy Krieger Institute shared thoughts on the state of pediatric neurology and the significance of being named winner of the Sydney Carter Award. [WATCH TIME: 3 minutes]
Using Large-Scale Data, AI to Assess Effective Migraine Treatment Options: Chia-Chun Chiang, MD
May 4th 2023The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]
Cenobamate as a Promising Treatment for Patients With Epilepsy: William E. Rosenfeld, MD, FAAN, FAES
May 3rd 2023The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Building a Neurology Space Inclusive of Diversity and Equity: Daniel Correa, MD, MSc
May 3rd 2023The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]
Serial Assessments Used in Groundbreaking Brain Study: Imad Najm, MD
May 2nd 2023The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]
Use of Other Amantadine Formulations in Parkinson Disease
The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.
Amantadine DR/ER for Dyskinesia in Parkinson Disease: Safety Profile and Ideal Patient
The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.
A Comprehensive Analysis of Stroke Prevalence Among Adults in the United States: Wells Andres, MD
May 1st 2023The neurology resident from the University of Pennslyvania talked about stroke prevalence in the United States between 1999 and 2018 as part of a presentation at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Initiating Difficult Conversations With Patients Based on Hard Data: Daniel Ontaneda, MD, PhD
April 30th 2023The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University provided commentary on the need for clinicians to be transparent with patients with MS about potential differences in disease course. [WATCH TIME: 3 minutes]
Clinical Research in ALS, the Potential of CNM-Au8 in the Care Landscape: James Berry, MD, MPH
April 28th 2023The director of the Massachusetts General Hospital ALS Care Center discussed the importance of effective disease-modifying therapies for ALS and the potential of CNM-Au8 in the management of the disease. [WATCH TIME: 2 minutes]
Providing Better Care to LGBTQ+ Patients With Multiple Sclerosis: William L. Conte, MD, MS
April 27th 2023The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University discusses the factors that affect the clinical care of LGBTQ+ patients with MS. [WATCH TIME: 4 minutes]
EEG as a Diagnostic Tool for Mild Cognitive Impairment: Andrew Budson, MD
April 27th 2023The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]
Postictal Generalized EEG Suppression as a Biomarker for SUDEP: Nancy R. Foldvary-Schaefer, DO, FAAN
April 27th 2023The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic discussed how additional sensors in seizure monitoring for patients with epilepsy may help better manage the risk of SUDEP. [WATCH TIME: 3 minutes]